



PTO/SB/08B(10-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	10/678,957
Filing Date	October 3, 2003
First Named Inventor	Veldhuis et al.
Group Art Unit	1647
Examiner Name	J. Galvez Schorras cym
Attorney Docket Number	2183-61411JS

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
TS		DEFAZIO et al., "ICAM expression and fluid phase endocytosis of cultured brain microvascular endothelial cells following exposure to interferon Beta-1a and TNF-Alpha," <i>Journal of Neuroimmunology</i> , 1998, pp. 13-20, vol. 88.	
		DHIB-JALBUT et al., "The effect of interferon Beta-1b on lymphocyte-endothelial cell adhesion," <i>Journal of Neuroimmunology</i> , 1996, pp. 215-222, vol. 71.	
		DOMANSKI et al., "Cloning and Expression of a Long Form of the Beta Subunit of the Interferon Alpha Beta Receptor That Is Required for Signaling," <i>The Journal of Biological Chemistry</i> , 15 September 1995, pp. 21606-21611, vol. 270, no. 37.	
		EMMETT et al., "Evaluation of Human Astrocytoma and Glioblastoma Cell Lines for Nerve Growth Factor Release," <i>Neurochem. Int.</i> , 1997, pp. 465-474, vol. 30, nos. 4/5.	
		THE ENLIMOMAB ACUTE STROKE TRIAL INVESTIGATORS, "The Enlimomab Acute Stroke Trial: Final Results," <i>Neurology</i> , March 1997, pp. A270, vol. 48.	
		THE ENLIMOMAB ACUTE STROKE TRAL INVESTIGATORS, "Use of anti-ICAM-1 therapy in ischemic stroke: Results of the Enlimomab Acute Stroke Trial," <i>Neurology</i> , October 2001, pp. 1428-1434, vol. 57.	
		GARLANDA et al., "Heterogeneity of Endothelial Cells: Specific Markers," <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, pp. 1193-1202, vol. 17.	
		KASTE et al., "Combined dexamethasone and low-molecular-weight dextran in acute brain infarction: double blind study," <i>Br Med J</i> , 11 December 1976, pp. 1409-1410, vol. 2, no. 6049. Abstract.	
		KRAMS et al., "Acute Stroke Therapy by Inhibition of Neutrophils (ASTIMS): An Adaptive Dose-Response Study of UK-279,276 in Acute Ischemic Stroke," <i>Stroke</i> , pp. 2543-2548, November 2003.	
		MULLEY et al., "Dexamethasone in acute stroke," <i>Br Med J</i> , 7 October 1978, pp. 994-996, vol. 2, no. 6143. Abstract.	
Q		NORRIS et al., "High dose steroid treatment in cerebral infarction," <i>Br Med J (Clin Res Ed.)</i> , 4 January 1986, pp. 21-23, vol. 292, no. 6512. Abstract.	

Examiner
Signature

G Sch

Date
Considered

11/16/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO		<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/678,957
<i>(use as many sheets as necessary)</i>		Filing Date	October 3, 2003
		First Named Inventor	Veldhuis et al.
		Group Art Unit	1647
		Examiner Name	J. Galvez <i>Seharaseyan</i>
Sheet	2	of	2
		Attorney Docket Number	2183-61411JS

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>JS</i>		NOVICK et al., "The Human Interferon Alpha/Beta receptor: Characterization and molecular Cloning," Cell, 6 May 1994, pp. 391-400, vol. 77.	
		QIZILBASH et al., "Corticosteroids for acute ischaemic stroke," The Cochrane Database of Systematic reviews, 2005, vol. 3. Abstract.	
		SOILU-HANNINEN et al., "Interferon-Beta down regulates expression of VLA-4 antigen and antagonizes interferon- γ -induced expression of HLA-DQ on human peripheral blood monocytes," Journal of Neuroimmunology, 1995, pp. 99-106, vol. 60.	
		TROJANO et al., "Effects of r IFN-Beta-1b on Serum circulating ICAM-1 in relapsing remitting multiple sclerosis and on the membrane-bound ICAM-1 expression on brain microvascular endothelial cells," Journal of NeuroVirology, 2000, pp. S47-S51, vol. 6.	
<i>Y</i>		UZE et al., "Genetic Transfer of a Functional Human Interferon Alpha Receptor into Mouse Cells: Cloning and Expression of Its cDNA," Cell, 26 January 1990, pp. 225-234, vol. 60.	

Examiner Signature	<i>JS</i>	Date Considered	<i>11/16/2003</i>
--------------------	-----------	-----------------	-------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.